Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Musculoskeletal | Rheumatology | Family Medicine | Neurology
Disease Category: Chronic Back Pain
Location: United States, GA
Clinical Trial Details
Research Study Summary
A Multicenter, 12-Week, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study To Determine The Efficacy And Safety Of ALO-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended Release Capsules In Subjects With Moderate To Severe Chronic Low Back Pain
The primary objective of the study is to determine the analgesic efficacy and safety of ALO-02 extended-release capsules, when compared to placebo, in subjects with moderate to severe chronic low back pain.
Patient Inclusion Criteria:
- Moderate to severe chronic low back pain present for at least 3 months.
- Require a continuous around-the-clock opioid analgesic for an extended period of time.
- Refrain from taking opioids and non-opioid analgesics during the study.
Patient Exclusion Criteria:
- Active or history of lumbosacral radiculopathy or chronic low back pain due to other underlying disorders such as cancer, infection, spinal stenosis or post-surgical intervention.
- Documented diagnosis of ongoing pain due to other chronic pain conditions which may interfer with assessment of chronic low back pain.
- Active or ongoing or history of alcohol or drug abuse.
To Learn more
Both Male and Female
Date Last Changed:
July 18, 2013
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these